Kura Oncology (NASDAQ:KURA) Issues Quarterly Earnings Results

Kura Oncology (NASDAQ:KURA) posted its earnings results on Wednesday. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11, FiscalAI reports. The company had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.

Here are the key takeaways from Kura Oncology’s conference call:

• KOMZIFTI generated $9.1 million in second-quarter net product revenue, with approximately 115 new patient starts and more than 250 prescriptions. Management said the drug captured a majority of new patient starts in the relapsed/refractory NPM1-mutated AML menin inhibitor market despite launching second.
• KOMZIFTI’s new patient starts increased about 35% sequentially and total prescriptions rose about 60%, while approximately 40% of new starts involved physician-initiated combination use. More than 95% of covered lives have access, including roughly 16 million lives with preferred coverage.
• Clinical data supported ziftomenib’s expansion into frontline AML and combination therapy, including a 94% 12-month overall survival rate in the frontline KOMET-007 dataset. The company expects additional FLT3 combination, long-term venetoclax, and other AML data in the second half of 2026, while pivotal KOMET-017 results remain targeted for 2028.
• Kura ended the quarter with $519 million in cash and short-term investments, down from $667.2 million at year-end 2025, and reported a $68.3 million net loss. Management said available funds plus expected Kyowa Kirin payments should fund the ziftomenib program through 2028, but further development of darlifarnib and potential registrational studies could require disciplined capital allocation or additional financing.
• Darlifarnib produced encouraging early combination data, including a 44% response rate in cabozantinib-exposed renal cell carcinoma and tumor shrinkage in 77% of response-evaluable patients receiving adagrasib in KRAS G12C-mutated cancers. A randomized renal cell carcinoma study is expected to complete enrollment in the first half of 2027, with initial data anticipated in the second half.

Kura Oncology Price Performance

Shares of KURA stock opened at $9.94 on Thursday. The business has a fifty day simple moving average of $10.15 and a 200 day simple moving average of $9.31. The company has a market cap of $882.37 million, a P/E ratio of -2.97 and a beta of 0.38. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. Kura Oncology has a twelve month low of $6.24 and a twelve month high of $12.49.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on KURA shares. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a research report on Monday, June 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Thursday, May 28th. Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, July 28th. Finally, Sanford C. Bernstein set a $24.00 price target on Kura Oncology in a research note on Monday, June 15th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.46.

Key Stories Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI momentum strengthened. The acute myeloid leukemia treatment generated $9.1 million in net product revenue, a 57% increase from the first quarter, while new patient starts rose 35% to approximately 115. This commercial growth suggests increasing adoption of Kura’s marketed product. Kura Oncology Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Financial results exceeded expectations. Kura reported a second-quarter loss of $0.77 per share, narrower than the $0.88–$0.89 analyst consensus, while revenue of $20.87 million topped expectations of approximately $20.16 million. The earnings beat may be contributing to the stock’s strength. Kura Oncology Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Collaboration revenue is expected to provide additional support. Management outlined approximately $90 million to $110 million of collaboration revenue for 2027, improving the company’s medium-term financial visibility. Kura Outlines 2027 Collaboration Revenue
• Neutral Sentiment: Clinical catalysts remain longer term. Kura is targeting topline results from the KOMET-017 study in 2028, leaving investors dependent on commercial execution and collaboration revenue in the nearer term. Kura Oncology Q2 2026 Earnings Call Transcript
• Negative Sentiment: Kura remains deeply unprofitable. Despite beating estimates, the company posted a substantial quarterly loss, with a reported negative net margin of 411.19%. Continued operating losses could limit valuation upside until product and collaboration revenue scale further. Kura Oncology Q2 2026 Earnings Call Summary

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the sale, the insider owned 182,345 shares in the company, valued at $1,790,627.90. The trade was a 31.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 7.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Kura Oncology during the 4th quarter worth approximately $349,000. Invesco Ltd. raised its stake in shares of Kura Oncology by 14.6% during the fourth quarter. Invesco Ltd. now owns 209,370 shares of the company’s stock valued at $2,175,000 after acquiring an additional 26,683 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Kura Oncology by 52.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 50,080 shares of the company’s stock worth $520,000 after purchasing an additional 17,197 shares during the period. Voloridge Investment Management LLC bought a new stake in shares of Kura Oncology in the fourth quarter worth $2,505,000. Finally, Virtus Investment Advisers LLC increased its holdings in Kura Oncology by 291.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 66,870 shares of the company’s stock valued at $695,000 after purchasing an additional 49,785 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.